Loading clinical trials...

Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age | Clinical Trials | Clareo Health

RECRUITINGNA

Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age

Parents' Enhanced Reminder Intervention to Improve Children's Timely Completion of Immunization Series of Pneumococcal Vaccine at the 12-month's Visit

NCT06000397•Ottawa Hospital Research Institute

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to assess the effectiveness of enhanced email reminders in improving vaccine coverage at the 12-month visit in CANImmunize app users. The main questions it aims to answer are: * Do enhanced email reminders improve coverage of the 12- month dose of the pneumococcal vaccine and the timely completion of its immunization series at the 12-month's visit in CANImmunize app users? * What are the predictors of predictors of timely completion of the 12-month's series of pneumococcal vaccines in the CANImmunize app users? Participants will be randomized to either receive enhanced reminder/recall materials via email or the standard CANImmunize notifications. Researchers will compare the enhanced reminder group to the standard notification group to see if there is a difference in vaccine coverage at the 12-month visit.

Eligibility

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•To be included in the study, CANImmunize account holders must have:
•Enabled the reception to receive emails from CANImmunize, and
•Record(s) for an infant aged between 10- and 11-months, who have already received the earlier doses of the pneumococcal vaccine in accordance with their provincial/territorial routine immunization schedule.

Exclusion Criteria

•The account holder (parent, or guardian of the child) has an inactive or undelivered email address, or
•No record(s) for an infant aged 10- and 11-months, or
•The record for the 10- or 11-month-old indicates that he/she has not received the prior pneumococcal vaccine doses.

Locations (1)

CANImmunize

Ottawa, Canada

Key Dates

Start Date

November 7, 2023

Primary Completion Date

June 1, 2024

Completion Date

June 1, 2024

Last Updated

April 9, 2024

Enrollment

700

ESTIMATED participants

Conditions

Pneumococcal VaccinesImmunization Coverage

Interventions

Enhanced reminders

OTHER

Standard CANImmunize notifications

OTHER

Contacts

Kathryn MacDonald

CONTACT

613-293-1193 kathryn@canimmunize.ca

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

NCT03893448

Pneumococcal InfectionsPneumococcal Vaccines

View study

COMPLETEDPHASE3

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children

NCT00824655

Pneumococcal Vaccines

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 9, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions